<DOC>
	<DOCNO>NCT00704795</DOCNO>
	<brief_summary>In order evaluate potential role gastrointestinal ( GI ) tract postprandial hyperglucagonemia , characterize type 1 diabetes mellitus ( T1DM ) ( well type 2 diabetes mellitus ( T2DM ) ) , wish investigate secretion glucagon patient T1DM without residual beta-cell function 50-g oral glucose tolerance test ( OGTT ) isoglycemic iv glucose infusion . By evaluate C-peptide negative patient T1DM aim describe glucagon response glucose ( +/-stimulation GI tract ) independently potentially important regulation glucagon secretion endogenous insulin secretion . A detailed understanding inappropriate glucagon secretion T1DM highly need order establish new intervention strategy future treatment grow number T1DM patient .</brief_summary>
	<brief_title>Glucagon Responses During Oral- iv Glucose Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Caucasian 18 year T1DM ( diagnose accord WHO 's criterion ) treat longacting insulin No residual betacell function ( arginine test without increment plasma Cpeptide see ) BMI &lt; 30 kg/m2 Normal haemoglobin Informed consent Residual betacell function ( increment plasma Cpeptide arginine test see ) Known liver disease affect liver enzymes ( ALAT/ASAT &gt; 2 x upper normal limit ) Diabetic nephropathy ( secreatinin &gt; 130 ÂµM and/or albuminuria ) Proliferative diabetic retinopathy ( anamnestic ) Treatment medication discontinue 14 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>